MediciNova (NASDAQ:MNOV – Get Free Report) and CorMedix (NASDAQ:CRMD – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.
Profitability
This table compares MediciNova and CorMedix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediciNova | -1,168.70% | -26.51% | -24.39% |
| CorMedix | 40.49% | 40.52% | 20.61% |
Earnings & Valuation
This table compares MediciNova and CorMedix”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MediciNova | $920,481.00 | 75.93 | -$12.00 million | ($0.21) | -6.76 |
| CorMedix | $457.20 million | 1.25 | $163.05 million | $2.14 | 3.44 |
CorMedix has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
9.9% of MediciNova shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 14.0% of MediciNova shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and price targets for MediciNova and CorMedix, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediciNova | 1 | 1 | 4 | 1 | 2.71 |
| CorMedix | 0 | 2 | 7 | 0 | 2.78 |
MediciNova currently has a consensus target price of $7.75, indicating a potential upside of 445.77%. CorMedix has a consensus target price of $15.00, indicating a potential upside of 103.80%. Given MediciNova’s higher probable upside, research analysts plainly believe MediciNova is more favorable than CorMedix.
Volatility and Risk
MediciNova has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.
Summary
CorMedix beats MediciNova on 11 of the 15 factors compared between the two stocks.
About MediciNova
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
About CorMedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.
